Anastasie M Dunn-Pirio1, Benjamin M Heyman2, Dan S Kaufman3, Revere P Kinkel1. 1. Division of Neuroimmunology, Department of Neurosciences, UC San Diego, La Jolla, CA, 92093, USA. 2. Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, UC San Diego, MC 0695, La Jolla, CA, 92093, USA. BHeyman@ucsd.edu. 3. Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, UC San Diego, MC 0695, La Jolla, CA, 92093, USA.
Abstract
PURPOSE OF REVIEW: This review presents a critical appraisal of the use of autologous hematopoietic cell transplant (AHCT) for the treatment of multiple sclerosis. We present the reader with a brief review on the AHCT procedure, its immunomodulatory mechanism of action in MS, the most recent evidence in support of its use in patients with relapsing-remitting multiple sclerosis (RRMS), as well as its cost considerations. RECENT FINDINGS: The first meta-analysis of clinical trials of AHCT for patients with MS demonstrated durable 5-year progression-free survival rates and low treatment-related mortality. Recently, the first randomized controlled phase III clinical trial demonstrated AHCT to be superior to best available therapy for a subset of patients with RRMS. This led to the American society for transplant and cellular therapies (ASTCT) to recommend AHCT "for patients with relapsing forms of MS who have prognostic factors that indicate a high risk of future disability." AHCT should be considered for patients with RRMS with evidence of clinical activity who have failed 2 lines of therapy or at least one highly active disease-modifying therapy.
PURPOSE OF REVIEW: This review presents a critical appraisal of the use of autologous hematopoietic cell transplant (AHCT) for the treatment of multiple sclerosis. We present the reader with a brief review on the AHCT procedure, its immunomodulatory mechanism of action in MS, the most recent evidence in support of its use in patients with relapsing-remitting multiple sclerosis (RRMS), as well as its cost considerations. RECENT FINDINGS: The first meta-analysis of clinical trials of AHCT for patients with MS demonstrated durable 5-year progression-free survival rates and low treatment-related mortality. Recently, the first randomized controlled phase III clinical trial demonstrated AHCT to be superior to best available therapy for a subset of patients with RRMS. This led to the American society for transplant and cellular therapies (ASTCT) to recommend AHCT "for patients with relapsing forms of MS who have prognostic factors that indicate a high risk of future disability." AHCT should be considered for patients with RRMS with evidence of clinical activity who have failed 2 lines of therapy or at least one highly active disease-modifying therapy.
Authors: G L Mancardi; M P Sormani; M Di Gioia; L Vuolo; F Gualandi; M P Amato; E Capello; D Currò; A Uccelli; A Bertolotto; C Gasperini; A Lugaresi; E Merelli; G Meucci; L Motti; M R Tola; E Scarpini; A M Repice; L Massacesi; R Saccardi Journal: Mult Scler Date: 2011-11-29 Impact factor: 6.312
Authors: Sofia V Abrahamsson; Daniela F Angelini; Amy N Dubinsky; Esther Morel; Unsong Oh; Joanne L Jones; Daniele Carassiti; Richard Reynolds; Marco Salvetti; Peter A Calabresi; Alasdair J Coles; Luca Battistini; Roland Martin; Richard K Burt; Paolo A Muraro Journal: Brain Date: 2013-07-17 Impact factor: 13.501
Authors: B J Bolwell; B Pohlman; L Rybicki; R Sobecks; R Dean; J Curtis; S Andresen; A Koo; V Mineff; M Kalaycio; J W Sweetenham Journal: Bone Marrow Transplant Date: 2007-07-09 Impact factor: 5.483
Authors: J D Bowen; G H Kraft; A Wundes; Q Guan; K R Maravilla; T A Gooley; P A McSweeney; S Z Pavletic; H Openshaw; R Storb; M Wener; B A McLaughlin; G R Henstorf; R A Nash Journal: Bone Marrow Transplant Date: 2011-11-07 Impact factor: 5.483
Authors: Bonaventura Casanova; Isidro Jarque; Francisco Gascón; Juan Carlos Hernández-Boluda; Francisco Pérez-Miralles; Javier de la Rubia; Carmen Alcalá; Jaime Sanz; Javier Mallada; Angeles Cervelló; Arantxa Navarré; María Carcelén-Gadea; Isabel Boscá; Sara Gil-Perotin; Carlos Solano; Miguel Angel Sanz; Francisco Coret Journal: Neurol Sci Date: 2017-04-10 Impact factor: 3.307
Authors: Navneet Singh Majhail; James Douglas Rizzo; Stephanie Joi Lee; Mahmoud Aljurf; Yoshiko Atsuta; Carmem Bonfim; Linda Jean Burns; Naeem Chaudhri; Stella Davies; Shinichiro Okamoto; Adriana Seber; Gerard Socie; Jeff Szer; Maria Teresa Van Lint; John Reid Wingard; Andre Tichelli Journal: Rev Bras Hematol Hemoter Date: 2012
Authors: Jennifer H Yang; Torge Rempe; Natalie Whitmire; Anastasie Dunn-Pirio; Jennifer S Graves Journal: Front Neurol Date: 2022-06-03 Impact factor: 4.086